Global Liraglutide Market Growth 2025-2031
The global Liraglutide market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. Marketed under the brand name Victoza, it is an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. In 2015, Novo Nordisk began marketing it in the U.S. under the brand name Saxenda as a treatment for obesity in adults with at least one weight-related comorbid condition.
United States market for Liraglutide is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Liraglutide is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Liraglutide is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Liraglutide players cover HEC Pharm, Bachem, Bharat Pharmaceuticals, Kingpep Biotechnology, Shenzhen JYMed Technology, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Liraglutide Industry Forecast” looks at past sales and reviews total world Liraglutide sales in 2024, providing a comprehensive analysis by region and market sector of projected Liraglutide sales for 2025 through 2031. With Liraglutide sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Liraglutide industry.
This Insight Report provides a comprehensive analysis of the global Liraglutide landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liraglutide portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Liraglutide market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liraglutide and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liraglutide.
This report presents a comprehensive overview, market shares, and growth opportunities of Liraglutide market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Pills
Liquid
Segmentation by Application:
Hospital
Drug Store
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
HEC Pharm
Bachem
Bharat Pharmaceuticals
Kingpep Biotechnology
Shenzhen JYMed Technology
Wuxi Asiapeptide
AmbioPharm
Key Questions Addressed in this Report
What is the 10-year outlook for the global Liraglutide market?
What factors are driving Liraglutide market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Liraglutide market opportunities vary by end market size?
How does Liraglutide break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.